RxDoctor Payments Data

James Williams

Family · Middlesboro, KYNPI 1477184331

Payments from drug & device makers

$951in general payments, 2019–2025

Across 32 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$474
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$101
  • Merck$91
  • AbbVie$74
  • Johnson & Johnson$43
  • Neurocrine Biosciences, Inc.$33
  • plus $135 from 6 others

What the payments were for

  • Travel & lodging$47450%
  • Food & beverage$47750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$951 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$960
Medicare patients
14
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$80,222
MounjaroTirzepatide47$55,337
LinzessLinaclotide52$36,350
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$28,450
EliquisApixaban40$26,826
SynjardyEmpagliflozin/Metformin Hcl28$21,519
JardianceEmpagliflozin27$18,362
JanuviaSitagliptin Phosphate22$14,700
BrilintaTicagrelor22$11,509
Combivent RespimatIpratropium/Albuterol Sulfate21$10,485
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen488$9,688
XareltoRivaroxaban11$8,675
Nicotrol NsNicotine15$7,921
Ventolin HfaAlbuterol Sulfate126$7,825
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$80,22284 claims
Boehringer IngelheimSynjardy, Jardiance, Combivent Respimat$12$50,36676 claims
AstraZenecaBreztri Aerosphere, Brilinta, Symbicort$31$43,51479 claims
AbbVieLinzess$74$36,35052 claims
PfizerEliquis$26$26,82640 claims
MerckJanuvia$91$14,70022 claims
Johnson & JohnsonXarelto$43$8,67511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Middlesboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →